Concepedia

Booster Dose Reactogenicity

Booster Dose Reactogenicity is a type of vaccine reactogenicity characterized by the intensity and profile of adverse reactions following an additional administration of a vaccine after the primary series, differentiating it from primary dose reactogenicity by its temporal spacing, immunological context, and often altered symptomatology.

90

Publications

4.3K

Citations

1.3K

Authors

290

Institutions

Publications per year

2017–2026

39

Parents

Publications

90

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Spyros Chalkias, Charles Harper, Keith Vrbicky et al. · New England Journal of Medicine · 2022 · 649 citations · Full text

, , +17

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

, , +17

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin et al. · The Lancet · 2021 · 258 citations · Full text

, , +17

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 177 citations · Full text

, , +16

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

Samba O. Sow, Brown J. Okoko, Aldiouma Diallo et al. · New England Journal of Medicine · 2011 · 174 citations · Full text

, , +17

1–5 of 90

Authors

1.3K

  1. LS
    Lode Schuerman

    GlaxoSmithKline (Belgium), Belgium

    8 publications · 244 citations

    8

    h-index

  2. AS
    Assad Safary

    GlaxoSmithKline (Belgium), Belgium

    4 publications · 240 citations

    4

    h-index

  3. DC
    David C. Montefiori

    Duke Medical Center, United States

    4 publications · 780 citations

    4

    h-index

  4. JM
    Jacqueline M. Miller

    Moderna Therapeutics (United States), United States

    4 publications · 778 citations

    4

    h-index

  5. RD
    Rituparna Das

    Moderna Therapeutics (United States), United States

    3 publications · 737 citations

    3

    h-index

1–5 of 1.3K

Institutions

290

  1. GlaxoSmithKline (Belgium)

    Wavre, Belgium

    11 h-index

    38 publications

    1.1K citations

  2. University of Oxford

    Oxford, United Kingdom

    4 h-index

    86 publications

    19.3K citations

  3. Chulalongkorn University

    Bangkok, Thailand

    3 h-index

    32 publications

    424 citations

  4. Brigham and Women's Hospital

    Boston, United States

    3 h-index

    5 publications

    1.5K citations

  5. Pfizer (United States)

    New York, United States

    3 h-index

    25 publications

    283 citations

  6. Tampere University

    Tampere, Finland

    3 h-index

    8 publications

    236 citations

  7. Wroclaw Medical University

    Wroclaw, Poland

    3 h-index

    4 publications

    78 citations

  8. Moderna Therapeutics (United States)

    Cambridge, United States

    3 h-index

    36 publications

    8.8K citations

1–8 of 290

Venues

  1. The Pediatric Infectious Disease Journal

    PIDJ · 13 publications · 524 citations

    12

    h-index

  2. Vaccine

    10 publications · 206 citations

    10

    h-index

  3. Human Vaccines & Immunotherapeutics

    HV&I · 6 publications · 118 citations

    6

    h-index

  4. BMJ

    5 publications · 222 citations

    5

    h-index

  5. Vaccines

    5 publications · 85 citations

    5

    h-index

1–5